Synthetic beta cells for fusion-mediated dynamic insulin secretion

Area of Science:

• Biomaterials Science
• Endocrinology
• Nanotechnology

Background:

• Diabetes mellitus requires precise glucose regulation, a function normally performed by pancreatic beta cells.
• Current diabetes therapies often lack the sophisticated glucose-sensing and responsive insulin secretion of native beta cells.
• Developing synthetic systems that mimic beta cell function is crucial for advanced diabetes management.

Purpose of the Study:

• To engineer artificial beta cells (AβCs) capable of glucose-responsive insulin secretion.
• To develop a robust synthetic system that mimics the natural insulin secretion mechanism of pancreatic beta cells.
• To create a multicompartmental vesicle system for controlled insulin release.

Main Methods:

• Construction of artificial beta cells (AβCs) with a 'vesicles-in-vesicle' superstructure.
• Incorporation of a glucose-metabolism system and membrane-fusion machinery within the AβCs.
• Utilizing a sequential cascade of glucose uptake, enzymatic oxidation, and proton efflux to trigger insulin release.

Main Results:

• The AβCs successfully distinguished between high and normal glucose levels.
• High glucose conditions led to a low pH (<5.6) within the AβCs, triggering a cascade.
• This cascade resulted in the fusion of inner and outer vesicles, leading to insulin exocytosis.

Conclusions:

• The developed AβCs demonstrate a functional mimicry of glucose-responsive insulin secretion.
• The 'vesicles-in-vesicle' design provides a robust platform for controlled insulin delivery.
• These artificial beta cells hold significant promise for improving clinical outcomes in diabetes management.